Similar to our results, Nettis et al. found that women treated with minocycline for treatment-resistant depression did not significantly differ from the placebo group in changes in IL-6, IL-1β, and TNF-α, after four weeks of treatment [59]. This evidence concerns the gene IL1B and depressive symptom measurement.